Insider Selling: Ocular Therapeutix (NASDAQ:OCUL) COO Sells $49,858.70 in Stock

Ocular Therapeutix, Inc. (NASDAQ:OCUL) COO Donald Notman sold 5,455 shares of the firm’s stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $9.14, for a total value of $49,858.70. Following the completion of the sale, the chief operating officer directly owned 383,837 shares in the company, valued at $3,508,270.18. This trade represents a 1.40% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Donald Notman also recently made the following trade(s):

• On Wednesday, February 4th, Donald Notman sold 6,035 shares of Ocular Therapeutix stock. The shares were sold at an average price of $8.54, for a total value of $51,538.90.

Ocular Therapeutix Trading Up 2.8%

Shares of Ocular Therapeutix stock opened at $9.16 on Friday. Ocular Therapeutix, Inc. has a 1 year low of $5.78 and a 1 year high of $16.44. The company’s fifty day simple moving average is $11.82 and its 200-day simple moving average is $11.93. The company has a market cap of $1.95 billion, a price-to-earnings ratio of -6.36 and a beta of 0.90. The company has a current ratio of 7.85, a quick ratio of 7.78 and a debt-to-equity ratio of 0.27.

Ocular Therapeutix (NASDAQ:OCUL) last released its earnings results on Thursday, February 5th. The biopharmaceutical company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.05. Ocular Therapeutix had a negative net margin of 511.90% and a negative return on equity of 94.79%. The firm had revenue of $13.25 million during the quarter. During the same quarter in the previous year, the company earned ($0.29) earnings per share. Ocular Therapeutix’s revenue for the quarter was down 22.4% compared to the same quarter last year. As a group, sell-side analysts expect that Ocular Therapeutix, Inc. will post -0.98 EPS for the current year.

Institutional Trading of Ocular Therapeutix

Large investors have recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC increased its holdings in shares of Ocular Therapeutix by 62.9% during the second quarter. Nisa Investment Advisors LLC now owns 3,604 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 1,392 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in Ocular Therapeutix by 17.0% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,154 shares of the biopharmaceutical company’s stock valued at $57,000 after purchasing an additional 893 shares in the last quarter. KBC Group NV bought a new position in Ocular Therapeutix in the 4th quarter valued at $78,000. Quarry LP acquired a new position in Ocular Therapeutix in the third quarter worth $80,000. Finally, Trust Co. of Vermont grew its holdings in shares of Ocular Therapeutix by 24.3% during the fourth quarter. Trust Co. of Vermont now owns 8,950 shares of the biopharmaceutical company’s stock worth $109,000 after purchasing an additional 1,750 shares during the last quarter. 59.21% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. Chardan Capital reiterated a “buy” rating and issued a $21.00 price objective on shares of Ocular Therapeutix in a research report on Tuesday, December 9th. Wall Street Zen raised Ocular Therapeutix from a “sell” rating to a “hold” rating in a research report on Saturday. Needham & Company LLC reiterated a “buy” rating and set a $20.00 price target on shares of Ocular Therapeutix in a research note on Monday, December 8th. Royal Bank Of Canada restated an “outperform” rating and issued a $30.00 price objective on shares of Ocular Therapeutix in a research note on Thursday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ocular Therapeutix in a report on Thursday, January 22nd. Eleven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $24.00.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.